Cargando…

Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Correction Notices
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355809/ https://www.ncbi.nlm.nih.gov/pubmed/35596941 http://dx.doi.org/10.1093/oncolo/oyac103

Ejemplares similares

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
Publicado: (2022)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
por: Lin, Hao, et al.
Publicado: (2023)

Correction to: Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Publicado: (2022)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Publicado: (2023)

Efficacy and Safety of Apatinib in the Treatment of Postoperative Recurrence of Fibrosarcoma
por: Ma, Huiwen, et al.
Publicado: (2020)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Correction to: Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018
Publicado: (2022)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
Publicado: (2023)

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure()
por: Cui, ChuanLiang, et al.
Publicado: (2018)

Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review
por: Khan, Aujala Irfan, et al.
Publicado: (2022)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

CORRECTION
Publicado: (2018)

Correction to: Management of Lung Cancer in the Patient with Interstitial Lung Disease
Publicado: (2023)

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
por: Yu, Jiangtao, et al.
Publicado: (2019)

Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma
por: Gu, Huiying, et al.
Publicado: (2020)

Correction Notice
Publicado: (2022)

Correction notice
Publicado: (2022)

Correction notice
Publicado: (2022)

Correction Notice
Publicado: (2017)

Correction Notice
Publicado: (2017)

Correction Notice
Publicado: (2019)

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
por: Zhang, Honghong, et al.
Publicado: (2017)

Correction Notice: Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm
Publicado: (2021)

Correction to: Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake
Publicado: (2023)

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial
por: Yu, Wenxi, et al.
Publicado: (2022)

The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Lin, Huixiong, et al.
Publicado: (2022)

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment
por: Bai, Ming, et al.
Publicado: (2021)

The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study
por: Nie, Caiyun, et al.
Publicado: (2021)

Correction Notice – Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
Publicado: (2023)

Correction Notice: The EHA Research Roadmap: Anemias
Publicado: (2021)

Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma
por: Lin, Guohe, et al.
Publicado: (2020)

Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report
por: Zhang, Yunchao, et al.
Publicado: (2020)

Correction Notice to Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population
Publicado: (2022)

Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
Publicado: (2022)

Correction Notice: Low-risk Essential Thrombocythemia: A Comprehensive Review
Publicado: (2022)

Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qka22u5utv06o2a60a51as5nl3